The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

X Gao, X Le, DB Costa - Expert review of anticancer therapy, 2016 - Taylor & Francis
First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …
被引用次数：73 相关文章
[HTML] nih.gov

[HTML][HTML] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

X Gao, X Le, DB Costa - Expert review of anticancer therapy, 2016 - ncbi.nlm.nih.gov
First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

X Gao, X Le, DB Costa - Expert review of anticancer …, 2016 - pubmed.ncbi.nlm.nih.gov
First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

X Gao, X Le, DB Costa - Expert Review of Anticancer Therapy, 2016 - europepmc.org
First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

X Gao, X Le, DB Costa - Expert review of …, 2016 - mdanderson.elsevierpure.com
First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

X Gao, X Le, DB Costa - Expert Review of Anticancer Therapy, 2016 - europepmc.org
First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …